title: Precision therapy to target apoptosis in prostate cancer.
abstract: Androgen-independent prostate cancer shows limited response to existing systemic therapies. Recent advances in prostate-selective targeting of small molecule inhibitors and bacterial toxins have created opportunities to design a new generation of therapies for advanced prostate cancer. Yet prioritizing targets for these therapies remain challenging, since multiple mechanisms contribute to the pathophysiology of androgen-independent prostate cancer. This review explores the possibility of targeting the apoptosis regulatory network as most direct approach to efficient treatment of advanced androgen-independent prostate cancer.
authors.affiliation: College of Science, Alfaisal University, Riyadh 11533, Saudi Arabia.
authors.forename: G
authors.initials: G
authors.lastname: Kulik
mesh_terms: D000728:Androgens / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D064549:Myeloid Cell Leukemia Sequence 1 Protein / Q000235:genetics / Q000378:metabolism; D009367:Neoplasm Staging; D010766:Phosphorylation; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D051025:bcl-Associated Death Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D000728:Androgens; D000970:Antineoplastic Agents; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D051025:bcl-Associated Death Protein